- In February 2024, Veriteque USA partnered with OraSure Technologies under a new distribution agreement. This collaboration enables OraSure to include Veriteque's SwabTek surface test kits in its lineup of oral fluid drug screening products. SwabTek offers single-use, dry reagent tests for narcotics and explosives, designed for use at home, in educational settings, and workplaces. The partnership expands OraSure's drug testing offerings, enhancing its ability to serve businesses, educators, and security professionals with comprehensive solutions.
- In March 2024, BioXcelerate, a pioneering health data science segment of Optima Partners Limited, unveiled a revolutionary AI tool designed to speed up the identification and development of new pharmaceuticals. The instrument, referred to as PleioGraph, can evaluate intricate medical data 100 times quicker than current leading techniques utilized to uncover biological networks that clarify disease risk and guide drug discovery.
- In December 2023, Quest Diagnostics introduced its new confirmatory testing service for new psychoactive substances (NPS). The updated panel, which checks for 88 substances, encompasses a wide range of drug categories, including designer opioids, designer benzodiazepines, designer stimulants, fentanyl derivatives, synthetic cannabinoids, and various illicit additives.
